Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
INTERVENTIONAL
Inicio: 24 de jul de 2020
ID: NCT04494425
Terminado
Fase 3
ClinicalTrials.gov
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 1 de feb de 2006
ID: NCT00300885
Completado
Fase 3
ClinicalTrials.gov
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00744497
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
INTERVENTIONAL
Inicio: 12 de ago de 2020
ID: NCT04428333
Desconocido
Fase 3
ClinicalTrials.gov
A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.
INTERVENTIONAL
Inicio: 1 de abr de 2007
ID: NCT00465491
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
INTERVENTIONAL
Inicio: 4 de jun de 2012
ID: NCT01597908
Completado
ClinicalTrials.gov
"Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia (CLL): Argentinian Experience"
OBSERVATIONAL
Inicio: 12 de ago de 2019
ID: NCT04016636
Completado
Fase 1
ClinicalTrials.gov
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
INTERVENTIONAL
Inicio: 9 de dic de 2022
ID: NCT05625412
Completado
ClinicalTrials.gov
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
OBSERVATIONAL
Inicio: 8 de abr de 2015
ID: NCT02303444
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
INTERVENTIONAL
Inicio: 11 de jun de 2019
ID: NCT03767244
Reclutando
Fase 3
ClinicalTrials.gov
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)
INTERVENTIONAL
Inicio: 6 de ene de 2025
ID: NCT06760637
Completado
Fase 2
ClinicalTrials.gov
See Detailed Description
INTERVENTIONAL
Inicio: 1 de feb de 2005
ID: NCT00169572
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
INTERVENTIONAL
Inicio: 25 de ene de 2019
ID: NCT03748641
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
INTERVENTIONAL
Inicio: 19 de ene de 2026
ID: NCT07216703
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
INTERVENTIONAL
Inicio: 14 de jul de 2022
ID: NCT05352672
Activo, no recluta
Fase 3
ClinicalTrials.gov
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
INTERVENTIONAL
Inicio: 26 de feb de 2020
ID: NCT03937154
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)
INTERVENTIONAL
Inicio: 19 de ene de 2023
ID: NCT05665595
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 27 de ago de 2012
ID: NCT01663727
Terminado
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgkin's Lymphoma
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00562965
Completado
Fase 2
ClinicalTrials.gov
A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion
INTERVENTIONAL
Inicio: 30 de sept de 2015
ID: NCT02576431
Anterior
1
...
54
55
56
...
434
Siguiente
Filtros